Technological advancements are set to play a key role in the overall growth of the global retinal disorders treatment market in the upcoming years. Groundbreaking breakthroughs and advancements in bionics, genetics, and stem-cell therapy are expected to transform the future of retinal disorders treatment in the upcoming decade. In developed regions wherein the preventable causes of blindness are detected early, owing to routine checkups and robust healthcare ecosystem, retinal degeneration has emerged as one of the top causes of blindness or visual impairment. Macular degeneration is of two types: wet age-related macular degeneration and dry age-related macular degeneration. Diabetic retinopathy is one of the common diabetic eye disorders characterized by damaged blood vessels in the retina. The damaged blood vessels and nerves lead to vision impairment, blurring of vision, and eye hemorrhage. If left untreated, it could lead to retinal detachment and blindness.
This report contains market size and forecasts of Retinal Disorders Treatment in Global, including the following market information:
Global Retinal Disorders Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Retinal Disorders Treatment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Gels Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Retinal Disorders Treatment include Allergan plc, Bayer AG, F., Hoffmann-La Roche Ltd., Graybug Vision, Inc., Kubota Pharmaceutical Holdings Co., Ltd., Novartis AG, Regeneron Pharmaceuticals, Inc., Santen Pharmaceutical Co., Ltd. and Takeda Pharmaceutical Company Limited and etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Retinal Disorders Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Retinal Disorders Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Retinal Disorders Treatment Market Segment Percentages, by Type, 2021 (%)
Gels
Ointments
Capsules & Tablets
Eye Drops
Global Retinal Disorders Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Retinal Disorders Treatment Market Segment Percentages, by Application, 2021 (%)
Macular Degeneration
Diabetic Retinopathy
Diabetic Macular Edema
Others
Global Retinal Disorders Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Retinal Disorders Treatment Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Retinal Disorders Treatment revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Retinal Disorders Treatment revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Allergan plc
Bayer AG, F.
Hoffmann-La Roche Ltd.
Graybug Vision, Inc.
Kubota Pharmaceutical Holdings Co., Ltd.
Novartis AG
Regeneron Pharmaceuticals, Inc.
Santen Pharmaceutical Co., Ltd.
Takeda Pharmaceutical Company Limited
Pfizer